Clearside Biomedical to Present at the 2018 UBS Global Health Care Conference
17 May 2018 - 6:30AM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical
biopharmaceutical company developing first-in-class drug therapies
to treat back-of-the-eye diseases, announced today that its Chief
Executive Officer and President, Daniel H. White, will present at
the 2018 UBS Global Health Care Conference on Tuesday, May 22, 2018
at 3:00 p.m. ET at the Grand Hyatt New York hotel in New York, NY.
A live webcast of the presentation can be
accessed on the company’s website at www.clearsidebio.com under the
“Events & Presentations” tab in the “Investor Relations”
section. Following the conference, the presentation webcast
will be archived on the website for approximately 30 days.
About Clearside
Clearside Biomedical, Inc., headquartered in
Alpharetta, GA, is a late-stage clinical ophthalmic
biopharmaceutical company that envisions a world without
blindness. Clearside relentlessly pursues transformative,
elegant, precise solutions to restore and preserve vision.
Clearside is developing advanced clinical and preclinical product
candidates using a proprietary treatment approach offering
unprecedented access to the back of the eye through the SCS™.
This has the potential to offer meaningful treatment benefit to
patients suffering from sight-threatening diseases like uveitis,
retinal vein occlusion, diabetic macular edema and wet age-related
macular degeneration. To learn more about how Clearside is
changing ophthalmology, please visit us at
www.clearsidebio.com.
Contacts:
Stephen KilmerInvestor Relations(678)
270-3631stephen.kilmer@clearsidebio.com
Charles DeignanChief Financial Officer(678)
270-4005charlie.deignan@clearsidebio.com
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Apr 2024 to May 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From May 2023 to May 2024